NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

Right…Flaskworks and the C Suites aren’t “central” to an MAA approval, but they are “central” to a transition from the B suites to the C suites to enable “large scale-up production” AFTER an approval.

And as you point out, that’s been the “long-term plan all along.”

From the recent PR:

The Company views use of the
Flaskworks closed system as key to enabling DCVax-L production to begin taking place in Grade C suites rather than Grade B suites – and the Company views such transition to Grade C suites as central to large scale-up of production.

The B suites should be able to handle the initial volume of patient treatments in the first year coming from the UK, while the C suites and the Flaskworks units are under development and validation. Meanwhile, the company would also be submitting their DCVax-L applications to the other regulators (Canada, US, EU) while this scale-up preparation was underway.

That’s been the long-term plan for the past several years, so I don’t understand why dennisdave is suddenly arguing there’s an entirely different pathway now upon the company’s announcement that they’re moving ahead with the plan they’ve intended all along?